Topical lactoferrin can improve stable psoriatic plaque

Giornale Italiano di Dermatologia e Venereologia

Volumn 149, Issue 3, 2014, Pages 335-340

  Saraceno, R ^a   Gramiccia, T ^a   Chimenti, S ^a   Valenti, P ^a   Pietropaoli, M ^b   Bianchi, L ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Biotechnology Society   (Italy)

Author keywords

Immune system; Interleukin 6; Lactoferrin; Psoriasis

Indexed keywords

LACTOFERRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TARGET LESION SCORE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; ANIMALS; CYTOKINES; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; ELBOW; FEMALE; FOLLOW-UP STUDIES; HUMANS; KNEE; LACTOFERRIN; MALE; MIDDLE AGED; OINTMENTS; PROSPECTIVE STUDIES; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84905637647     PISSN: 03920488     EISSN: 18271820     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Saraceno R, Mannheimer R, Chimenti S. Regional Distribution of psoriasis in Italy. J Eur Acad Dermatol Venereol 2008;22:324-9. (Pubitemid 351247422)
2. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-5. (Pubitemid 30626007)
3. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000;42:796-802. (Pubitemid 30252885)
4. Linder D, Sampogna F, Torreggiani A, Balato N, Bianchi L, Cassano N et al. Psodisk, a new visual method for assessing the burden of psoriasis on patients. J Eur Acad Dermatol Venereol 2012;26:1163-5.
5. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487-98; 499-502.
6. Chiricozzi A, Zhang S, Dattola A, Gabellini M, Chimenti S, Nistico SP. Role of Th17 in the pathogenesis of cutaneous inflammatory diseases. J Biol Regul Homeost Agents 2012;26:313-8.
7. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
8. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 2009;124:R13-8.
9. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J. Lactoferrin structure and functions. Adv Exp Med Biol 2008;606:163-94.
10. Rodríguez-Franco DA, Vázquez-Moreno L, Ramos-Clamont Montfort G. Antimicrobial mechanisms and potential clinical application of lactoferrin. Rev Latinoam Microbiol 2005;47:102-11.
11. Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci 2005;62:2576-87. (Pubitemid 41721231)
12. Ward PP, Conneely OM. Lactoferrin: role in iron homeostasis and host defense against microbial infection. Biometals 2004;17:203-8. (Pubitemid 38987138)
13. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int J Exp Pathol 1993;74:433-9. (Pubitemid 23304079)
14. Crouch SP, Slater KJ, Fletcher J. Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 1992;80:235-40.
15. Kimura A, Naka T, Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA 2007;104:12099-104. (Pubitemid 47185636)
16. Schultz KF, Altman DG, Moher D. The CONSORT Group. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel-Group Randomized Trials. Trials 2010;11:32.
17. Frednksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44. (Pubitemid 8387357)
18. Bullen JJ, Rogers HJ, Leigh L. Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. Br Med J 1972;1:69.
19. Bullen JJ, Rogers HJ, Griffiths E. Role of iron in bacterial infection. Curr Top Microbiol Immunol 1978;80:1.
20. Reiter B. Review of nonspecific antimicrobial factors in colostrum. Ann Rech Vet 1978;9:205.
21. Cumberbatch M, Bhushan M, Dearman RJ, Kimber I, Griffiths CE. IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin. Clin Exp Immunol 2003;132:352-9. (Pubitemid 36560635)
22. Paesano R, Pietropaoli M, Gessani S, Valenti P. The influence of lactoferrin, orally administered, on systemic iron homeostasis in pregnant women suffering of iron deficiency and iron deficiency anaemia. Biochimie 2009;91:44-51.
23. Gilliet M, Lande R. Antimicrobial peptides and self-DNA in auto-immune skin inflammation. Curr Opin Immunol 2008;20:401-7.
24. Büchau AS, Gallo RL. Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol 2007;25:616-24. (Pubitemid 350087608)
25. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007;449:564-9. (Pubitemid 47525141)
26. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-43. (Pubitemid 41002916)
27. Drouin R, Moroni O, Cantin K, Juneau C. A double-blind, placebo-controlled, randomized trial of XP-828L (800 mg) on the quality of life and clinical symptoms of patients with mild-to-moderate psoriasis. Altern Med Rev 2008;13:145-52. (Pubitemid 352009503)
28. Poulin Y, Bissonnette R, Juneau C, Cantin K, Drouin R, Poubelle PE. XP-8281 in the treatment of mild to moderate psoriasis: randomized, double-blind, placebo-controlled study. J Cutan Med Surg 2006;10:241-8. (Pubitemid 351506637)
29. Kamili QU, Menter A. Topical treatment of psoriasis. Curr Probl Dermatol 2009;38:37-58.
30. Girolomoni G, Vena GA, Ayala F, Cannavò SP, De Pità O, Chimenti S et al. Consensus on the use of the fixed combination calcipotriol/ betamethasone dipropionate in the treatment of plaque psoriasis. G Ital Dermatol Venereol 2012;147:609-24.
31. Calzavara-Pinton P, Rossi MT, Sala R, Venturini M. The separate daily application of tacalcitol 4 μg/g ointment and budesonide 0.25 mg/g cream is more effective than the single daily application of a two compound ointment containing calcipotriol 50 μg/g and betamethasone dipropionate 0.5 mg/g. G Ital Dermatol Venereol 2011;146:295-9.